Using vitamin C to improve treatment for acute myeloid leukemia
Enhancing TET activity for the treatment of hematological malignancy
This study is looking at whether vitamin C can help treat people with acute myeloid leukemia, especially those with a specific gene mutation, by boosting the body's ability to fight cancer and making other treatments work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project ID | NIH-10895423 on NIH RePORTER |
What this research studies
This research investigates the potential of vitamin C as a non-toxic treatment option for patients with acute myeloid leukemia (AML), particularly those with TET2 mutations. The study aims to enhance the activity of TET enzymes, which are crucial for regulating gene expression and preventing cancer cell growth. By using vitamin C, the researchers hope to promote DNA demethylation and improve the effectiveness of existing therapies, ultimately leading to better patient outcomes. The approach involves both cellular and animal models to assess the impact of vitamin C on leukemia progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older diagnosed with acute myeloid leukemia, particularly those with TET2 mutations.
Not a fit: Patients with acute myeloid leukemia who do not have TET2 mutations may not benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results using vitamin C in similar contexts, suggesting that this approach may be effective for treating AML.
Where this research is happening
Coral Gables, United States
- University of Miami School of Medicine — Coral Gables, United States (Active)
Researchers
- Principal investigator: Cimmino, Luisa — University of Miami School of Medicine
- Study coordinator: Cimmino, Luisa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.